These results contribute to the growing body of knowledge on the multifaceted benefits of SGLT-2 inhibitors, underscoring their role not only as effective hypoglycemic agents but also as essential cardiovascular and renal protectors in patients with both HF and T2DM. Here, SLC5A2 is linked to hydrops fetalis.